Abstract
In maxillofacial surgery, the generally accepted method of treating ameloblastoma (malignancy 1.5-4%) is a radical removal of the formation with a resection of the lower jaw within healthy tissues. However, given the relatively favorable clinical course of ameloblastoma of the first and second groups of AB, we believe that radicalism should be reasonably sufficient in order not to disable the patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
